Although downregulated in lung cancer due to the hypermethylation of its promoter, lncAGER exhibits the anti-tumor function by first targeting miR-185, thereby increasing the advanced glycosylation end-product specific receptor (AGER) level in lung cancer cells, which is an important innate immune pattern-recognition receptor, and ultimately promoting the anti-tumor effect of human monocytes [117]. The gene discussed is AGER; the disease is lung carcinoma.